The Amyloidosis Channel is supported with funding from Prothena (Silver).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2019 | MRD as a prognostic tool in amyloidosis
Surbhi Sidana, MBBS Mayo Clinic, Rochester, MN, discusses preliminary data regarding the role of measurable residual disease (MRD) as a prognostic tool in light-chain amyloidosis, drawing on results from studies at the Mayo clinic. This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.
